Proof of concept demonstration of optimal composite MRI endpoints for clinical trials

Atrophy measures derived from structural MRI are promising outcome measures for early phase clinical trials, especially for rare diseases such as primary progressive aphasia (PPA), where the small available subject pool limits our ability to perform meaningfully powered trials with traditional cognitive and functional outcome measures.

• Publication year

  2016

• Venue

  Alzheimer's & Dementia

• Publication date

  2016-07-04

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.trci.2016.05.002PMID 28345017PMCID 5363955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimal composite scores for longitudinal clinical trials under the linear mixed effects model

  2015cited by this paper
• Empowering imaging biomarkers of Alzheimer's disease.

  2015cited by this paper
• Asymmetry of cortical decline in subtypes of primary progressive aphasia

  2014influential reference
• Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

  2013cited by this paper
• Combining Multiple Markers to Improve the Longitudinal Rate of Progression: Application to Clinical Trials on the Early Stage of Alzheimer's Disease

  2013cited by this paper
• Within-subject template estimation for unbiased longitudinal image analysis

  2012cited by this paper
• Classification of primary progressive aphasia and its variants

  2011cited by this paper
• Power Calculations for Clinical Trials in Alzheimer's Disease

  2011influential reference
• Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease

  2010cited by this paper
• Primary progressive aphasia and kindred disorders.

  2008cited by this paper
• Endpoints for trials in Alzheimer's disease: a European task force consensus.

  2008cited by this paper
• An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

  2006cited by this paper
• Primary progressive aphasia--a language-based dementia.

  2003cited by this paper
• Cortical surface-based analysis. I. Segmentation and surface reconstruction.

  1999cited by this paper

• Implications of practice effects for the design of Alzheimer clinical trials

  2025cites this paper
• Optimal Weighting of Preclinical Alzheimer’s Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer’s Disease Clinical Trials

  2023influential citation
• Association of Regional Cortical Network Atrophy With Progression to Dementia in Patients With Primary Progressive Aphasia

  2022cites this paper
• Neuroimaging in Frontotemporal Lobar Dementia: Research and Clinical Utility

  2022influential citation
• Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility.

  2021cites this paper
• Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

  2020cites this paper
• Clinical and cortical decline in the aphasic variant of Alzheimer's disease

  2019cites this paper
• Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease

  2019cites this paper
• Sex-specific composite scales for longitudinal studies of incipient Alzheimer’s disease

  2019cites this paper
• Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease

  2017cites this paper
• Alzheimer's trials.

  2017cites this paper
• Design of pilot studies to inform the construction of composite outcome measures

  2017cites this paper
• Potential implications of practice effects in Alzheimer's disease prevention trials

  2017cites this paper